These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30198601)

  • 1. Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
    Pitarokoili K; Höffken N; Lönneker N; Fisse AL; Trampe N; Gold R; Reinacher-Schick A; Yoon MS
    J Neuroimaging; 2019 Jan; 29(1):133-139. PubMed ID: 30198601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
    Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings.
    Briani C; Campagnolo M; Lucchetta M; Cacciavillani M; Dalla Torre C; Granata G; Bergamo F; Lonardi S; Zagonel V; Cavaletti G; Ermani M; Padua L
    Eur J Neurol; 2013 Jan; 20(1):188-92. PubMed ID: 22943629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
    Tong H; Fan Z; Liu B; Lu T
    Sci Rep; 2018 Jun; 8(1):8666. PubMed ID: 29875415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
    Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
    Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroneurography in the evaluation of oxaliplatin-induced neuropathy in colorectal cancer patients.
    Zygulska AL; Banach M; Krzemieniecki K
    Neoplasma; 2016; 63(4):617-22. PubMed ID: 27268926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
    Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
    Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
    Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
    Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
    Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients.
    He M; Sun J; Zhao D; He H; Wang B; Xu L; Shang Y; Ren S; Zhang Y; Wu T
    Int J Hyperthermia; 2019; 36(1):394-402. PubMed ID: 30917701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
    Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
    Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.